CarryGenes Therapeutics - Stockholm, Sweden

CarryGenes Therapeutics has developed a revolutionary platform called Cromo-T, which seeks to shift the paradigm of immunotherapy and target advanced-stage cancers. This technology consists of a T-cell containing a human Synthetic Chromosome (hSynC) that is capable of introducing new genetic information into the human body without being integrated into the subject's current genome. This new genetic information can then be used to perform a variety of functions.